Clinical trials: Esophagogastric Junction
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04771520
- Testing
- Avapritinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Stomach, Gastroesophageal Junction Expressing Guanylyl Cyclase C
A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with recurrent or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the stomach or gastroesophageal junction.
- Trial name
- NCT02202759
- Testing
- MLN0264
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 38 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Dysphagia, Esophageal, Esophageal Cancer
Validation of Instruments Used for Assessment of Dysphagia in Patients With Esophageal Cancer
This study validates 3 well known dysphagia scores for dysphagia due to malignancies of the oesophagus and gastro-oesophageal junction and to the Swedish language.
- Trial name
- NCT03066167
- Testing
- Validation of different dysphagia scores
- Where
- Sweden
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This study is designed to evaluate the efficacy and safety of Camrelizumab plus pyrotinib in combination with chemotherapy in patients with HER2-positive gastric cancer.
- Trial name
- NCT05111444
- Testing
- Camrelizumab, Pyrotinib, Capecitabine
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fudan University
Gastric Cancer
SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Neoadjuvant chemotherapy or chemoradiotherapy has become the standard neoadjuvant regimen for locally advanced G/GEJ cancer and has been recommended by a series of treatment guidelines.
- Trial name
- NCT06266871
- Testing
- SOX+Tislelizumab+LDRT
- Volunteers
- 64 people
- Sponsor
- West China Hospital
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
This phase I trial investigates how well pembrolizumab and chemoradiotherapy works in treating patients with gastroesophageal cancer that cannot be removed by surgery (unresectable).
- Conditions
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04522336
- Testing
- Docetaxel, Fluorouracil, Oxaliplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Gastroesophageal-junction Cancer
Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer
Background: The prevalence of gastroesophageal-junction cancer (cancer between the distal part of the oesophagus, and proximal part of the stomach/GEJ-cancer) is increasing in Denmark with more than 400 patients per year.
- Trial name
- NCT02085564
- Testing
- Peritoneal washing cytology
- Where
- Denmark
- Volunteers
- 87 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
B Cell Lymphoma, B Cell Leukemia
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR T cells in patients with malignant tumors with positive antigen targets.
- Conditions
- B Cell Lymphoma, B Cell Leukemia, Myeloma, Hepatocellular Carcinoma
- Trial name
- NCT03302403
- Testing
- CAR-CD19 T cell, CAR-BCMA T cell, CAR-GPC3 T cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Kang YU
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
This study aims to evaluate the efficacy and safety of SHR-A1811 combined with chemotherapy and immune checkpoint inhibitor versus standard first-line therapy in gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT07118527
- Testing
- SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil Injection, Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin)
- Where
- 2 sites in China
- Volunteers
- 600 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer
This is a single-arm, multi-center phase II clinical study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With advanced gastric cancer or gastroesophageal junction cancer.
- Trial name
- NCT05395780
- Testing
- MAX-40279
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Maxinovel Pty., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer
GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)
This is a prospective, non-interventional, observational, multicentre study evaluating the real-world effectiveness and safety of AstraZeneca-developed and approved medicines used to treat gastric and/or oesophageal cancers in…
- Trial name
- GRACE-DE (NCT07882212)
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Gastric (Stomach) Cancer
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to evaluate the objective response rate (ORR) of Pembrolizumab combined with Lenvatinib and SOX compared with SOX alone in the treatment of patients with HER2-negative advanced gastric or…
- Trial name
- FUGES032 (NCT07356466)
- Testing
- Pucotenlimab Combined with Lenvatinib, Oxaliplatin plus S-1 regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fujian Medical University
Gastric Cancer
T900607 in Treating Patients With Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have…
- Trial name
- NCT00054249
- Testing
- T900607
- Where
- United States
- Sponsor
- University Hospitals Seidman Cancer Center
Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
RATIONALE: Pralatrexate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT01129206
- Testing
- pralatrexate, docetaxel, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Gastric / Gastroesophageal Junction Adenocarcinoma
Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin
This study is a prospective, open-label, two-arm exploratory Phase II clinical trial aimed at observing and evaluating the efficacy and safety of combined therapy with cadonilimab and fruquintinib in conjunction with…
- Trial name
- NCT06406426
- Testing
- Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Advanced Solid Tumor
Study of SRF617 in Patients With Advanced Solid Tumors
A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.
- Trial name
- NCT04336098
- Testing
- SRF617, Gemcitabine, Albumin-Bound Paclitaxel
- Where
- 10 sites in United States, Canada
- Volunteers
- 85 people
- Sponsor
- Coherus Oncology, Inc.
Locally Advanced Unresectable Gastric Adenocarcinoma
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
The efficacy and safety of combination with Cadonilimab and CapeOX Regimen for neoadjuvant treatment of resectable locally advanced adenocarcinoma of the gastro-esophageal junction.
- Trial name
- NCT05974059
- Testing
- Oxaliplatin, Capecitabine, Cadonilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Solid Tumors
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
This phase I dose escalation study is intended to define the safety, tolerability and maximal tolerable dose (MTD) of MT110 in patients with advanced solid tumors.
- Trial name
- MT110-101 (NCT00635596)
- Testing
- MT110
- Where
- 4 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Amgen Research (Munich) GmbH
Esophageal Cancer
Trimodality Management of T1b Esophageal Cancers
The goal of this clinical research study is to learn if giving chemotherapy and radiation therapy before surgery for early-stage esophageal cancer can help to control the disease and if so, for how long.
- Trial name
- NCT01217060
- Testing
- Docetaxel, 5-FU, Radiotherapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer, Gastroesophageal Junction Cancer
Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea
This study is designed to gather epidemiological data in Korea on HER2 incidence in gastric and gastroesophageal junction cancer as assessed by local laboratories in a real-life setting.
- Trial name
- NCT02538562
- Where
- 14 sites in South Korea
- Volunteers
- 1,695 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.